Rapid progress in genomic sequencing and high-throughput methods has made the molecular characterization of many complex diseases, especially cancer, possible. Ongoing international efforts have focused on collecting and sequencing a wide variety of human neoplasms and documenting the interaction between therapeutic compounds and genetic alterations. The analysis and integration of these vast amounts of data has, in turn, prompted complex problems with solutions requiring advanced quantitative, systems-level approaches.
At the Center for Systems and Computational Biology (CSCB) at Rutgers Cancer Institute of New Jersey, a group of computational biologists, geneticists, molecular pathologists, and clinical oncologists develop new quantitative and experimental approaches to improve diagnosis, understand disease pathogenesis, discover new disease-driving aberrations, and design effective clinical trials and precise treatment strategies for patients under active care.
The Center extensively collaborates with scientists at Rutgers and beyond including the Rutgers Discovery Informatics Institute (RDI2), the Institute for Quantitative Biomedicine (IQB), the Human Genetics Institute of New Jersey (HGINJ), and the New Jersey Alliance for Clinical and Translational Science (NJ ACTS) .